• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Forte Biosciences Inc. (Amendment)

    2/14/24 4:11:58 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBRX alert in real time by email
    SC 13G/A 1 d744272dsc13ga.htm FORTE BIOSCIENCES, INC. Forte Biosciences, Inc.

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Forte Biosciences, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    34962G109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 34962G109

     

      1.    

      Names of Reporting Persons

     

      Alger Associates, Inc. 13-3017981

      2.    

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.    

      SEC Use Only

     

      4.    

      Citizenship or Place of Organization

     

      New York

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

        5.     

      Sole Voting Power

     

      1,838,965

      6.     

      Shared Voting Power

     

      0

      7.     

      Sole Dispositive Power

     

      1,838,965

      8.     

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,838,965

    10.    

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.    

      Percent of Class Represented by Amount in Row (9)

     

      5.1%

    12.    

      Type of Reporting Person (See Instructions)

     

      HC

     

    2


    Item 1.    
      (a)   Name of Issuer
       

    Forte Biosciences, Inc.

      (b)  

    Address of Issuer’s Principal Executive Offices

    3060 Pegasus Park Drive, Building 6

    Dallas, TX 75247

    Item 2.    
      (a)   Name of Person Filing
       

    Alger Associates, Inc.

      (b)   Address of Principal Business Office or, if none, Residence
       

    100 Pearl Street, 27th Floor, New York, NY 10004

      (c)   Citizenship
       

    New York

      (d)   Title of Class of Securities
       

    Common Stock

      (e)   CUSIP Number
       

    34962G109

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a)  

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

      (b)  

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

      (c)      

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

      (d)  

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

      (e)  

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

      (f)  

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

      (g)  

    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

      (h)  

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

      (i)  

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

      (j)  

    ☐   A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

      (k)  

    ☐   Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                                 

     

    3


    Item 4.        Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)    Amount beneficially owned:
         

    1,838,965

       (b)    Percent of class:
         

    5.1%

       (c)        Number of shares as to which the person has:
         

     

              (i)    Sole power to vote or to direct the vote
            

    1,838,965

              (ii)    Shared power to vote or to direct the vote
            

    0

              (iii)    Sole power to dispose or to direct the disposition of
            

    1,838,965

              (iv)      Shared power to dispose or to direct the disposition of
            

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (“FAM”), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A

     

    Item 8.

    Identification and Classification of Members of the Group

     

    Item 9.

    Notice of Dissolution of Group

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    By:   Alger Associates, Inc.
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   February 14, 2024

     

    5


    Exhibit A

    Subsidiary

    Alger Group Holdings, LLC* — HC

    Fred Alger Management, LLC* — IA

    * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

    Get the next $FBRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBRX

    DatePrice TargetRatingAnalyst
    8/18/2025$75.00Buy
    Guggenheim
    1/21/2025Buy
    TD Cowen
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    9/20/2021$4.00 → $3.50Sell → Buy
    Chardan Capital Markets
    9/20/2021$4.00 → $3.50Sell → Neutral
    Chardan Capital
    9/3/2021Buy → Hold
    Brookline Capital
    9/3/2021Buy → Neutral
    Ladenburg Thalmann
    9/3/2021$105.00 → $4.00Buy → Sell
    Chardan Capital Markets
    More analyst ratings

    $FBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A bought $124,998 worth of shares (22,514 units at $5.55), increasing direct ownership by 273% to 30,776 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    11/22/24 5:45:42 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $7,525 worth of shares (10,000 units at $0.75), increasing direct ownership by 0.55% to 1,823,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/20/23 10:56:32 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $14,551 worth of shares (20,520 units at $0.71), increasing direct ownership by 1% to 1,813,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/15/23 6:29:33 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.77% to 31,599 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:22:07 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 80,940 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:20:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 0.71% to 31,218 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    4/2/25 5:03:05 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    12/6/24 4:05:50 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:31:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:02:27 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Leadership Updates

    Live Leadership Updates

    View All

    Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

    Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

    6/20/23 8:00:00 AM ET
    $CABA
    $FBRX
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

     -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

    -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forte Biosciences, Inc. Announces Results and Provides Update

    Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. "I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly." said Forte Biosciences CEO Paul Wagner, PhD. "We have begun dosing subjects in the FB102 phase 2 celiac disease clinical trial and look forward to reporting to

    8/14/25 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Announces Pricing of $75 Million Public Offering

    Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to

    6/25/25 12:28:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Announces Proposed Public Offering

    Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in the offering. All of the shares of common stock and pre-funded warrants are being offered by Forte. The proposed offering is subject to

    6/24/25 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

    SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    8/14/25 4:27:46 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Forte Biosciences Inc.

    10-Q - Forte Biosciences, Inc. (0001419041) (Filer)

    8/14/25 4:16:07 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Forte Biosciences, Inc. (0001419041) (Filer)

    8/14/25 4:07:56 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Forte Biosciences with a new price target

    Guggenheim initiated coverage of Forte Biosciences with a rating of Buy and set a new price target of $75.00

    8/18/25 8:56:30 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Forte Biosciences

    TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

    1/21/25 7:45:55 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

    4/8/24 7:21:57 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Financials

    Live finance-specific insights

    View All

    Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

    Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

    6/23/25 7:18:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub

    9/2/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also

    8/16/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care